Thromb Haemost 2024; 124(12): 1171-1176
DOI: 10.1055/s-0044-1791679
Letter to the Editor

Reply to “Commentary: ‘No Genetic Causality between Tobacco Smoking and Venous Thromboembolism: A Two-Sample Mendelian Randomization Study’ ”

Hong-Cheng Du
1   Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Graduate School of Guangxi University of Chinese Medicine, Nanning, China
,
Yun-Fei Zheng
1   Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Graduate School of Guangxi University of Chinese Medicine, Nanning, China
,
Meng-Qi Shen
1   Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Graduate School of Guangxi University of Chinese Medicine, Nanning, China
,
Bai-Yang Deng
1   Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Graduate School of Guangxi University of Chinese Medicine, Nanning, China
› Author Affiliations

Commentary: “No Genetic Causality between Tobacco Smoking and Venous Thromboembolism: A Two-Sample Mendelian Randomization Study”

We recently received comments on our findings[1] from Liu et al for which we are grateful, and we appreciate their careful scholarship and thoughtfulness. We would like to respond to the comments of Liu et al as follows:

First, Liu et al argue that a major issue in our study is the failure to account for sample overlap. However, as pointed out by Liu et al, the bias due to sample overlap is mainly due to false-positive errors, whereas our findings are not significant. However, we also replaced venous thromboembolism (VTE) data from different data sources ([Table 1])[2] for validation in this response, and the results showed that our conclusions were stable ([Table 2]).

Table 1

Summary information on the included exposure/outcome phenotypes

Phenotypic name

No. of cases

No. of controls

Sample size

Ancestry

Sex

Consortium (cohort)/author

Public release year

Study reference or description URL

Age of initiation of regular smoking

NA

NA

728,826

Mixed (84.35%European)

Both sexes

GSCAN/Gretchen R. B. Saunders et al[3]

2022

Nature. 2022 Dec;612(7941):720–724. doi: 10.1038/s41586-022-05477-4.

Ever smoked regularly

NA

NA

3,383,199

Mixed (79.11%European)

Both sexes

GSCAN/Gretchen R. B. Saunders et al[3]

2022

Nature. 2022 Dec;612(7941):720–724. doi: 10.1038/s41586-022-05477-4.

Cigarettes per day

NA

NA

784,353

Mixed (79.03%European)

Both sexes

GSCAN/Gretchen R. B. Saunders et al[3]

2022

Nature. 2022 Dec;612(7941):720–724. doi: 10.1038/s41586-022-05477-4.

Smoking cessation

NA

NA

1,400,535

Mixed (82.26%European)

Both sexes

GSCAN/Gretchen R. B. Saunders et al[3]

2022

Nature. 2022 Dec;612(7941):720–724. doi: 10.1038/s41586-022-05477-4.

Venous thromboembolism

21,021

391,160

412,181

European

Both sexes

FinnGen.R10/Mitja I. Kurki et al[2]

2023

https://www.finngen.fi/en

Deep venous thrombosis

6,501

357,111

363,612

European

Both sexes

FinnGen.R10/Mitja I. Kurki et al[2]

2023

https://www.finngen.fi/en

Pulmonary embolism

10,046

401,128

411,174

European

Both sexes

FinnGen.R10/Mitja I. Kurki et al[2]

2023

https://www.finngen.fi/en

Table 2

Associations of smoking-related phenotypes with VTE (including its subtypes) estimated by five MR methods

Outcome

Exposure

Method

No. of SNPs

Beta

SE

p-Value

OR (95% CI)

Venous thromboembolism

Age of initiation of regular smoking

Inverse variance weighted

6

0.332

0.253

0.190

1.393 (0.848, 2.289)

MR Egger

6

[minus]0.043

0.630

0.949

0.958 (0.279, 3.291)

Weighted median

6

0.124

0.285

0.663

1.132 (0.648, 1.979)

Weighted mode

6

0.054

0.383

0.894

1.055 (0.498, 2.235)

Simple mode

6

[minus]0.051

0.449

0.913

0.950 (0.394, 2.290)

Ever smoked regularly

Inverse variance weighted

254

0.099

0.053

0.064

1.104 (0.994, 1.225)

MR Egger

254

0.360

0.193

0.063

1.433 (0.982, 2.092)

Weighted median

254

0.108

0.070

0.122

1.114 (0.971, 1.278)

Weighted mode

254

0.136

0.210

0.517

1.146 (0.759, 1.729)

Simple mode

254

0.167

0.221

0.451

1.182 (0.766, 1.822)

Cigarettes per day

Inverse variance weighted

61

0.116

0.065

0.076

1.123 (0.988, 1.276)

MR Egger

61

0.065

0.108

0.548

1.067 (0.864, 1.319)

Weighted median

61

0.022

0.076

0.769

1.022 (0.881, 1.186)

Weighted mode

61

0.047

0.067

0.481

1.048 (0.920, 1.194)

Simple mode

61

0.225

0.155

0.152

1.252 (0.924, 1.696)

Smoking cessation

Inverse variance weighted

18

[minus]0.030

0.108

0.785

0.971 (0.785, 1.201)

MR Egger

18

0.151

0.316

0.639

1.163 (0.627, 2.159)

Weighted median

18

[minus]0.073

0.157

0.641

0.930 (0.684, 1.263)

Weighted mode

18

0.003

0.191

0.989

1.003 (0.690, 1.457)

Simple mode

18

0.024

0.245

0.922

1.025 (0.633, 1.657)

Past tobacco smoking

Inverse variance weighted

95

[minus]0.144

0.084

0.089

0.866 (0.734, 1.022)

MR Egger

95

[minus]0.450

0.348

0.200

0.638 (0.322, 1.263)

Weighted median

95

[minus]0.091

0.097

0.345

0.913 (0.755, 1.103)

Weighted mode

95

0.041

0.224

0.857

1.041 (0.671, 1.616)

Simple mode

95

0.008

0.231

0.973

1.008 (0.641, 1.585)

Current tobacco smoking

Inverse variance weighted

35

0.188

0.299

0.530

1.206 (0.671, 2.168)

MR Egger

35

[minus]0.593

1.114

0.598

0.553 (0.062 ,4.902)

Weighted median

35

0.054

0.375

0.885

1.056 (0.507, 2.200)

Weighted mode

35

[minus]0.087

0.589

0.883

0.916 (0.289, 2.908)

Simple mode

35

0.248

0.709

0.729

1.281 (0.319, 5.143)

Deep venous thrombosis

Age of initiation of regular smoking

Inverse variance weighted

6

0.988

0.482

0.041

2.685 (1.043, 6.910)

MR Egger

6

1.759

1.188

0.213

5.809 (0.566, 59.662)

Weighted median

6

1.485

0.469

0.002

4.417 (1.762, 11.073)

Weighted mode

6

1.572

0.574

0.041

4.817 (1.562, 14.848)

Simple mode

6

1.499

0.693

0.083

4.478 (1.151, 17.416)

Ever smoked regularly

Inverse variance weighted

254

0.204

0.093

0.028

1.226 (1.023, 1.470)

MR Egger

254

0.440

0.337

0.193

1.553 (0.802, 3.006)

Weighted median

254

0.214

0.125

0.087

1.239 (0.969, 1.584)

Weighted mode

254

0.483

0.325

0.139

1.620 (0.857, 3.064)

Simple mode

254

0.539

0.389

0.167

1.714 (0.800, 3.671)

Smoking cessation

Inverse variance weighted

18

[minus]0.104

0.190

0.586

0.901 (0.621, 1.309)

MR Egger

18

0.679

0.546

0.232

1.972 (0.676, 5.755)

Weighted median

18

0.049

0.250

0.844

1.050 (0.643, 1.715)

Weighted mode

18

0.120

0.348

0.733

1.128 ( 0.571, 2.229)

Simple mode

18

0.047

0.428

0.915

1.048 (0.453, 2.425)

Cigarettes per day

Inverse variance weighted

61

0.065

0.085

0.441

1.067 (0.904, 1.260)

MR Egger

61

[minus]0.062

0.139

0.657

0.940 (0.715, 1.235)

Weighted median

61

[minus]0.099

0.125

0.430

0.906 (0.709, 1.158)

Weighted mode

61

[minus]0.036

0.118

0.762

0.965 (0.766, 1.216)

Simple mode

61

0.389

0.275

0.161

1.476 (0.862, 2.529)

Past tobacco smoking

Inverse variance weighted

95

[minus]0.159

0.120

0.184

0.853 (0.675, 1.078)

MR Egger

95

[minus]0.307

0.496

0.537

0.736 (0.278, 1.945)

Weighted median

95

[minus]0.150

0.165

0.363

0.861 (0.623, 1.189)

Weighted mode

95

[minus]0.173

0.360

0.631

0.841 (0.415 ,1.704)

Simple mode

95

[minus]0.447

0.442

0.314

0.640 (0.269 ,1.520)

Current tobacco smoking

Inverse variance weighted

35

[minus]0.182

0.418

0.664

0.834 (0.367 ,1.892)

MR Egger

35

[minus]0.523

1.543

0.737

0.593 (0.029 ,12.211)

Weighted median

35

0.405

0.580

0.485

1.500 (0.481 ,4.677)

Weighted mode

35

0.747

1.133

0.514

2.111 (0.229 ,19.464)

Simple mode

35

0.888

1.279

0.492

2.430 (0.198 ,29.813)

Pulmonary embolism

Age of initiation of regular smoking

Inverse variance weighted

6

0.307

0.292

0.292

1.360 (0.768 ,2.408)

MR Egger

6

0.265

0.762

0.745

1.304 (0.293 ,5.805)

Weighted median

6

0.238

0.386

0.538

1.269 (0.595 ,2.706)

Weighted mode

6

0.273

0.476

0.591

1.314 (0.517 ,3.340)

Simple mode

6

0.157

0.562

0.792

1.170 (0.388 ,3.521)

Ever smoked regularly

Inverse variance weighted

254

0.169

0.071

0.017

1.184 (1.031 ,1.359)

MR Egger

254

0.460

0.256

0.073

1.584 (0.959 ,2.617)

Weighted median

254

0.167

0.100

0.095

1.181 (0.972 ,1.436)

Weighted mode

254

0.454

0.281

0.108

1.574 (0.907 ,2.733)

Simple mode

254

0.454

0.318

0.155

1.574 (0.843 ,2.939)

Smoking cessation

Inverse variance weighted

18

0.094

0.154

0.543

1.098 (0.812 ,1.486)

MR Egger

18

0.115

0.442

0.799

1.121 (0.472 ,2.667)

Weighted median

18

0.218

0.211

0.303

1.243 (0.822 ,1.880)

Weighted mode

18

0.209

0.244

0.404

1.232 (0.763 ,1.990)

Simple mode

18

0.144

0.305

0.642

1.155 (0.635 ,2.102)

Cigarettes per day

Inverse variance weighted

61

0.119

0.093

0.200

1.127 (0.939 ,1.352)

MR Egger

61

0.137

0.154

0.377

1.147 (0.848 ,1.552)

Weighted median

61

0.038

0.104

0.714

1.039 (0.848 ,1.273)

Weighted mode

61

0.014

0.096

0.885

1.014 (0.840 ,1.223)

Simple mode

61

[minus]0.015

0.253

0.953

0.985 (0.599 ,1.619)

Past tobacco smoking

Inverse variance weighted

95

[minus]0.051

0.113

0.652

0.950 (0.761 ,1.186)

MR Egger

95

[minus]0.061

0.469

0.898

0.941 (0.375 ,2.361)

Weighted median

95

0.125

0.140

0.374

1.133 (0.861 ,1.490)

Weighted mode

95

0.343

0.332

0.303

1.410 (0.736 ,2.700)

Simple mode

95

0.225

0.389

0.564

1.252 (0.584 ,2.685)

Current tobacco smoking

Inverse variance weighted

35

0.675

0.421

0.109

1.963 (0.860 ,4.480)

MR Egger

35

[minus]0.490

1.566

0.757

0.613 (0.028 ,13.205)

Weighted median

35

0.258

0.502

0.607

1.295 (0.484 ,3.464)

Weighted mode

35

[minus]0.086

0.868

0.921

0.917 (0.167 ,5.031)

Simple mode

35

1.307

1.038

0.217

3.694 (0.483 ,28.267)

Abbreviation: MR, Mendelian randomization.


Second, Liu et al identified a second major issue in this study is the choice of data, including the use of outdated datasets and an incomplete consideration of the exposure phenotype. In response to their point about outdated datasets, we employed the Round 10 VTE GWAS (genome-wide association study) summary statistics released in 2023 by FinnGen in our current response, and it is clear that the results ([Table 2]) are also consistent with our previous findings.

Incomplete consideration of smoking phenotypes, which we must recognize as correct, does not affect our results. Please note that we also included this time four smoking phenotypes ([Table 1])[3] published by the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) in 2022, and the results showed that the association of all six smoking phenotypes with VTE was not statistically significant ([Table 2]). As for their subtypes, we note that the inverse variance-weighted (IVW) method suggests possible age of initiation of regular smoking–DVT (deep vein thrombosis), ever smoked regularly–DVT, and ever smoked regularly–PE (pulmonary embolism) associations ([Table 2]), but we must point out that the age of initiation of regular smoking–DVT association suffers from too small several instrumental variables and large differences in the estimates of the five methods. As for the ever smoked regularly–DVT and ever smoked regularly–PE associations, none of the methods were significant except for the IVW method. Moreover, considering that the associations of all six smoking phenotypes with VTE were not statistically significant, the significant results in their subtypes should be treated with caution.

In addition, and also due to the third question posed to us by Liu et al, the instrumental variables addressed in our current response did not undergo the exclusion of single nucleotide polymorphisms (SNPs) associated with confounders to control for horizontal pleiotropy as described in our previous studies.[1] For the conflicting association results in VTE and its subtypes, it is likely that bias due to SNPs associated with confounders was attributed.



Publication History

Received: 30 July 2024

Accepted: 15 September 2024

Article published online:
03 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 
  • References

  • 1 Du HC, Zheng YF, Shen MQ, Deng BY. No genetic causality between tobacco smoking and venous thromboembolism: a two-sample Mendelian randomization study. Thromb Haemost 2024; 124 (08) 795-802
  • 2 Kurki MI, Karjalainen J, Palta P. et al; FinnGen. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 2023; 613 (7944) 508-518
  • 3 Saunders GRB, Wang X, Chen F. et al; 23andMe Research Team, Biobank Japan Project. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature 2022; 612 (7941) 720-724